7 results about "Peg interferon" patented technology

The present invention provides compounds of formula I for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonosis, nonalcoholic steatohepatitis (NASH), interstitial lung disease (ILD), and idiopathic pulmonary fibrosis (IPF). JPEG2026504613000125.jpg8493 (in the formula, R 1 , R 2 , R 3 , R 4 , A, D, E, G, J, K, and L are as defined in claim 1), and prodrugs, deuterated analogs, and pharmaceutically acceptable salts thereof.

The invention discloses application of licoflavone A in resisting viral hepatitis B, and belongs to the technical field of medicine application. The licoflavone A is used for treating viral hepatitis B. The licoflavone A used in the invention shows good safety and tolerance in HepG2.2. 15 and HepG2.A64 cells, can play a role in resisting HBV under the condition of no obvious cytotoxicity, and has significant advantages compared with interferon drugs in the prior art with long treatment course, large side effect and poor tolerance.

The invention relates to compounds of formula I wherein R1, R2, R3, A, D, E, G, J, K and L are as defined in claim 1; as well as prodrugs, deuterated analogs and pharmaceutically acceptable salts thereof; the compounds are useful in the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferon lesions, non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).

The invention generally relates to the field of diagnostics and prognostics. In particular, the invention relates to a method for determining the responsiveness of a chronic hepatitis B (CHB) patient to IFN-alpha treatment. In an aspect of the invention, there is provided a method for determining the responsiveness of a chronic hepatitis B (CHB) patient to IFN-alpha treatment, comprising: (a) measuring an expression level of at least one biomarker of a prognostic biomarker panel selected from the group consisting of NQO2, MBL2, IGKV3D-20, PKHD1L1, PGLYRP1, KHSRP, LCN2, and ROBO1 in a biological sample obtained from the patient, and (b) comparing the expression level of the at least one biomarker to corresponding expression level of a known non-responder, wherein an expression level higher than the corresponding expression level is indicative of a likelihood of a positive response to IFN-alpha treatment.

The invention relates to compounds of formula (I), wherein R1 is selected from the group consisting of H, C1-3-alkyl, C1-3-haloalkyl, -CH2-CO-NH2, -CH2-CO-NHCH3 and -CH2-CO-N(CH3)2 R2 is selected from the group consisting of H, halogen, (C1-3)-alkyl and halo-(C1-3)-alkyl, R3 is selected from the group consisting of C1-3-alkyl, five- or six-membered heterocyclic ring with 1 to 3 heteroatoms selected from N, O, S or SO2 and a five- or six-membered carbocyclic ring, wherein R3 is substituted by one or two substituents R8 which are each independently selected from the group consisting of H, C1-3-alkyl, -CO-O-(C1-4-alkyl), halogen, CN, OH, O-C1-3-methyl and -CO-(C1-3-alkyl), wherein each V, U, Q and T are independently from each other selected from C or N, wherein R4 is selected from the group consisting of H, halogen, -methyl, -O-C1-3-haloalkyl and -C1-3-haloalkyl, wherein R5 is selected from H, halogen, methyl, -O-C1-3-haloalkyl and -C1-3-haloalkyl, wherein R6 is selected from H, halogen, methyl, -O-C1-3-haloalkyl and -C1-3-haloalkyl, wherein R7 is selected from H, halogen, methyl, -O-C1-3-haloalkyl and -C1-3-haloalkyl, and pharmaceutical acceptable salts thereof, for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonopathies, metabolic dysfunction associated Steatohepatitis (MASH), interstitial lung disease (ILD), decompensated liver cirrhosis and idiopathic pulmonary fibrosis (IPF).

This invention discloses a liquid heat-resistant protective agent, its preparation method, and its application. The liquid heat-resistant protective agent comprises solution A and solution B in a volume ratio of 1:1. Solution A consists of the following components by weight-volume percentage: polyethylene glycol 2-8%, trehalose 2-6%, EDTA-2Na 0.1-2%, Tween-80 0.2-1.5%, with the balance being water for injection. Solution B consists of the following components by weight-volume percentage: dextran 1-6%, D-sorbitol 0.5-6%, histidine 0.25-6.5%, with the balance being water for injection. This liquid heat-resistant protective agent disclosed in this invention enables recombinant chicken interferon injection to be stably stored for 27 months at 2-8°C, 2 months at room temperature (25±2°C), and 1 month at 37°C. Compared with freeze-drying, the preparation process of this liquid protective agent is simple, and its application only requires mixing the liquid protective agent with the recombinant chicken interferon injection, eliminating the need for a freeze-drying step, thereby reducing production costs and cold chain transportation costs.